[go: up one dir, main page]

CR9390A - Mutaciones del receptor del factor de crecimiento epidermico - Google Patents

Mutaciones del receptor del factor de crecimiento epidermico

Info

Publication number
CR9390A
CR9390A CR9390A CR9390A CR9390A CR 9390 A CR9390 A CR 9390A CR 9390 A CR9390 A CR 9390A CR 9390 A CR9390 A CR 9390A CR 9390 A CR9390 A CR 9390A
Authority
CR
Costa Rica
Prior art keywords
mutations
growth factor
epidermal growth
egfr
factor receiver
Prior art date
Application number
CR9390A
Other languages
English (en)
Inventor
Freeman Daniel
Juan Todd
Radinsky Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR9390A publication Critical patent/CR9390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G01N33/575—
    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen mutaciones del receptor del factor de crecimiento epidermico (EGFR), de la proteina fosfatidilinositol 3-cinasa (PI3K) y de la protein cinasa B-RAF. Se describen metodos para el tratamiento de tumores que contienen polipeptidos EGFR mutantes, empleando anticuerpos monoclonales de origen humano dirigidos contra el polipeptido EGFR.
CR9390A 2005-02-24 2007-09-24 Mutaciones del receptor del factor de crecimiento epidermico CR9390A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
CR9390A true CR9390A (es) 2008-01-02

Family

ID=36579263

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9390A CR9390A (es) 2005-02-24 2007-09-24 Mutaciones del receptor del factor de crecimiento epidermico

Country Status (15)

Country Link
US (2) US7981605B2 (es)
EP (1) EP1851243A2 (es)
JP (2) JP2008535477A (es)
KR (1) KR20070106029A (es)
CN (1) CN101208354A (es)
AU (2) AU2006216477A1 (es)
BR (1) BRPI0607235A2 (es)
CA (1) CA2601936C (es)
CR (1) CR9390A (es)
EA (1) EA013617B1 (es)
IL (1) IL185210A0 (es)
MX (1) MX2007009963A (es)
NO (1) NO20074826L (es)
WO (1) WO2006091899A2 (es)
ZA (1) ZA200707379B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952338A (zh) * 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
ES2586410T3 (es) 2005-02-11 2016-10-14 Memorial Sloan-Kettering Cancer Center Procedimientos y composiciones de detección de un mutante de EGFR resistente a fármacos
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
ES2609094T3 (es) * 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
CN101675075B (zh) 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
AR065686A1 (es) * 2007-03-13 2009-06-24 Amgen Inc Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP2313758B1 (en) * 2008-07-17 2012-02-01 Koninklijke Philips Electronics N.V. Nanopore device and a method for nucleic acid analysis
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
DK3301446T3 (da) * 2009-02-11 2020-06-29 Caris Mpi Inc Molekylær tumorprofilering
US8623604B2 (en) * 2009-09-09 2014-01-07 Quintiles Transnational Corp. Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA
SG186335A1 (en) * 2010-07-07 2013-01-30 Eisai R&D Man Co Ltd Method for production of tumor cells from normal mammary epithelial cells
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
US9222137B2 (en) * 2011-05-10 2015-12-29 Trovagene, Inc. Method for monitoring minimal residual hairy cell leukemia
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
KR20150136588A (ko) * 2013-01-14 2015-12-07 내셔널 타이완 유니버시티 Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
EP3829593A4 (en) * 2018-07-31 2022-04-13 Ascentage Pharma (Suzhou) Co., Ltd. Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
KR102370550B1 (ko) * 2019-01-11 2022-03-08 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
WO2020145715A1 (ko) * 2019-01-11 2020-07-16 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
KR102286025B1 (ko) * 2019-01-11 2021-08-05 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
PH12021552030A1 (en) 2019-02-26 2022-08-15 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
EP4005593A4 (en) * 2019-07-24 2023-08-16 Sinocelltech Ltd. MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
JP2975679B2 (ja) * 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
CA2408175A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
AU2003272361A1 (en) * 2002-09-11 2005-04-11 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
US7932026B2 (en) 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
KR20150043558A (ko) * 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
ES2402469T3 (es) * 2005-04-13 2013-05-06 Astex Therapeutics Limited Derivados de hidroxibenzamida y sus usos como inhibidores de la Hsp90
ES2398709T5 (es) 2005-06-28 2017-04-18 Genentech, Inc. Mutaciones en EGFR y KRAS para predecir la respuesta de un paciente al tratamiento con inhibidores de EGFR

Also Published As

Publication number Publication date
US20070048754A1 (en) 2007-03-01
CN101208354A (zh) 2008-06-25
BRPI0607235A2 (pt) 2009-08-25
EA200701804A1 (ru) 2008-06-30
AU2010241462A1 (en) 2010-12-16
EA013617B1 (ru) 2010-06-30
CA2601936A1 (en) 2006-08-31
JP2008535477A (ja) 2008-09-04
US8546107B2 (en) 2013-10-01
IL185210A0 (en) 2008-01-06
MX2007009963A (es) 2007-09-26
KR20070106029A (ko) 2007-10-31
ZA200707379B (en) 2008-10-29
US20120328620A1 (en) 2012-12-27
WO2006091899A3 (en) 2007-02-22
CA2601936C (en) 2014-06-17
WO2006091899A2 (en) 2006-08-31
JP2012149070A (ja) 2012-08-09
NO20074826L (no) 2007-11-23
EP1851243A2 (en) 2007-11-07
US7981605B2 (en) 2011-07-19
AU2006216477A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
CR9390A (es) Mutaciones del receptor del factor de crecimiento epidermico
MX2021004775A (es) Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NZ743881A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
EP2010911A4 (en) TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
CY1119172T1 (el) ΑΝΤΙΣΩΜΑ ANTI-cMET
WO2009068625A3 (en) Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
IL191788A0 (en) Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
EA201070012A1 (ru) МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ
EP2365750A4 (en) BENZOXAZOLE KINASE INHIBITORS AND METHOD FOR THEIR USE
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos